A CD-19-specific CAR-NK cells phase I/II clinical trial involving eleven patients with relapsed/refractory(R/R) CD19-positive cancers (NHL or CLL) showed no cytokine release syndrome, neurotoxicity or GvHD. The gene discussed is CD19; the disease is cancer.